Condensed Statements of Changes in Shareholders’ Deficit (Unaudited) - USD ($)		Ordinary Shares Class A	Ordinary Shares Class B	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at Jun. 09, 2024
Balance (in Shares) at Jun. 09, 2024
Class B ordinary shares issued to Sponsor	[1]		$ 767	24,233		25,000
Class B ordinary shares issued to Sponsor (in Shares)	[1]		7,665,900
Net income (loss)					(28,263)	(28,263)
Balance at Jun. 30, 2024			$ 767	24,233	(28,263)	(3,263)
Balance (in Shares) at Jun. 30, 2024			7,665,900
Balance at Dec. 31, 2024			$ 575	24,425	(91,980)	(66,980)
Balance (in Shares) at Dec. 31, 2024			5,750,000
Remeasurement of Class A ordinary shares subject to redemption				(7,333,504)	(7,355,888)	(14,689,392)
Sale of Private Placement Units		$ 67		6,443,683		6,443,750
Sale of Private Placement Units (in Shares)		672,875
Sale of Restricted Shares		$ 57		284,943		285,000
Sale of Restricted Shares (in Shares)		570,000
Fair Value of Public Warrants at issuance				603,750		603,750
Allocated value of transaction costs to Class A shares				(60,047)		(60,047)
Share-based compensation				36,750		36,750
Net income (loss)					1,182,055	1,182,055
Balance at Mar. 31, 2025		$ 124	$ 575		(6,265,813)	(6,265,114)
Balance (in Shares) at Mar. 31, 2025		1,242,875	5,750,000
Balance at Dec. 31, 2024			$ 575	24,425	(91,980)	(66,980)
Balance (in Shares) at Dec. 31, 2024			5,750,000
Net income (loss)						2,811,282
Balance at Jun. 30, 2025		$ 124	$ 575		(6,503,595)	(6,502,896)
Balance (in Shares) at Jun. 30, 2025		1,242,875	5,750,000
Balance at Mar. 31, 2025		$ 124	$ 575		(6,265,813)	(6,265,114)
Balance (in Shares) at Mar. 31, 2025		1,242,875	5,750,000
Remeasurement of Class A ordinary shares subject to redemption					(1,867,009)	(1,867,009)
Net income (loss)					1,629,227	1,629,227
Balance at Jun. 30, 2025		$ 124	$ 575		$ (6,503,595)	$ (6,502,896)
Balance (in Shares) at Jun. 30, 2025		1,242,875	5,750,000

[1] Included an aggregate of up to 999,900 Class B ordinary shares that were subject to forfeiture by the holders thereof depending on the extent to which the underwriter’s over-allotment option is exercised (see Note 5).